Clinical data from patients treated under an investigational protocol for TPOXX (tecovirimat) support continuing to make the smallpox antiviral drug available to treat U.S. patients with monkeypox during the current outbreak, according to a report released today by the Centers for Disease Control and Prevention. The CDC protocol includes patient treatment and adverse event reporting forms to monitor safety and ensure intended clinical use. 

“Initial findings indicate that tecovirimat is likely well tolerated; among reported adverse events, most were not serious, and it is not known whether tecovirimat caused the adverse events reported,” the report notes. “… However, no control group was available for comparison; therefore, no conclusions can be drawn regarding the effectiveness of tecovirimat to treat monkeypox based on these data.”

In related news, the National Institutes of Health today announced it is enrolling U.S. adults and children with monkeypox infection in a Phase 3 clinical trial to evaluate the antiviral drug.

Related News Articles

Headline
The World Health Organization today recommended a new name for monkeypox that is intended to mitigate a rise in related racist and stigmatizing language…
Headline
The Department of Health and Human Services today renewed the nation’s monkeypox public health emergency declaration for another 90 days. When the PHE was…
Headline
As the monkeypox outbreak slows in the U.S., a new report from the Centers for Disease Control and Prevention highlights devastating outcomes of monkeypox for…
Headline
The Centers for Disease Control and Prevention today reported the first U.S. monkeypox case in a health care worker since the outbreak began in May. The report…
Headline
The Food and Drug Administration Friday authorized for emergency use the first commercial test kit to detect monkeypox in lesion swab specimens. Only…
Headline
Health and Human Services Secretary Xavier Becerra last week extended for 10 years his Aug. 4 public health emergency for monkeypox under the Public Readiness…